Search Patents
  • Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
    Publication number: 20230406907
    Abstract: The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 21, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Xia Cao, Lucy Lu, Ying Yan, Yanliang Zhang, Henry Hongjun Ji, Robert Allen
  • STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF
    Publication number: 20220325279
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus “S” spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Application
    Filed: December 28, 2021
    Publication date: October 13, 2022
    Applicants: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Daniel ELLIS, Neil KING, Jesse BLOOM, Tyler STARR, Allison GREANEY
  • SARS-COV-2 PROTEINS, ANTI-SARS-COV-2 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20230279078
    Abstract: The present disclosure provides SARS-CoV-2 spike proteins and trimers containing such spike proteins. The present disclosure also provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2. The proteins, trimers, and antibodies can be used, for example, to detect anti-SARS-CoV-2 antibodies in sample obtained from a subject.
    Type: Application
    Filed: July 19, 2021
    Publication date: September 7, 2023
    Inventors: GLEN HUGHES, RUTH E. MARCH, MARK ESSER, PATRICK MCTAMNEY II, YUEH-MING LOO, REENA M. VARKEY, QUN DU, JAMES STEINHARDT, SARAVANAN RAJAN
  • Super-antigen fusion proteins and the use thereof
    Publication number: 20060134753
    Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment encoding a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid of the peptide fragment encoding the partial SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The present invention further relates to DNA sequences encoding the partial SARS E2 spike protein includes SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, or SEQ ID NO.8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.
    Type: Application
    Filed: July 19, 2005
    Publication date: June 22, 2006
    Applicant: Healthbanks Biotech Co., Ltd.
    Inventors: Hsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
  • Super-antigen fusion proteins and the use thereof
    Patent number: 7618635
    Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment whose sequence corresponds to a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid sequence of the peptide fragment corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention further relates to DNA sequences corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: November 17, 2009
    Assignee: Healthbanks Biotech Co., Ltd.
    Inventors: Hsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
  • VARIANT SARS-CoV-2 PROTEINS AND USES THEREOF
    Publication number: 20230302116
    Abstract: The present disclosure relates to variants of SARS-CoV-2 nucleocapsid protein, spike protein, and spike protein receptor binding domain (RBD), as well as nucleic acids encoding such variants and methods of use thereof. Such variants are useful in diagnostic test kits and vaccines for SARS-CoV-2.
    Type: Application
    Filed: May 5, 2021
    Publication date: September 28, 2023
    Inventors: Ariel H. HECHT, Seth C. Ritter, Emily E. Wrenbeck
  • ANTIVIRUS PROTEINS HAVING A KRINGLE 5 SUBUNIT
    Publication number: 20210324047
    Abstract: COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 21, 2021
    Inventor: Donald J. DAVIDSON
  • FUSION PROTEIN AND METHOD OF DETECTING BACTERIA HAVING PSEUDAMINIC ACID
    Publication number: 20230140486
    Abstract: A fusion protein including a phage tail-spike protein ?AB6TSP and a signal indicator is provided. Also, a method of detecting bacteria having pseudaminic acid (Pse) is provided, including steps of contacting a sample with a phage tail-spike protein ?DAB6TSP; and detecting a signal from the sample. The fusion protein and the method of detecting bacteria can be applied to a set of practical diagnosis and therapeutic alternative against Pse-coated antibiotic resistant pathogenic bacteria.
    Type: Application
    Filed: April 14, 2021
    Publication date: May 4, 2023
    Applicant: Academia Sinica
    Inventors: Shih-Hsiung WU, I-Ming LEE
  • Immunogenic Coronavirus Fusion Proteins and Related Methods
    Publication number: 20230399364
    Abstract: Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion proteins, with surface-exposed trimers of the ectodomain of the Spike protein of the coronavirus, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 14, 2023
    Applicants: The Board of Trustees of the Leland Stanford Junior University, CZ Biohub SF, LLC
    Inventors: Abigail E. Powell, Payton Anders-Benner Weidenbacher, Natalia Friedland, Mrinmoy Sanyal, Peter S. Kim
  • COMPOSITION AND METHOD TO STABILIZE CORONAVIRUS SPIKE GLYCOPROTEINS IN PRE-FUSION CONFORMATION
    Publication number: 20230357325
    Abstract: Compositions include coronavirus S1/S2 prefusion spike proteins with specifically designed disulfide bond that “staple” together the central helix and a region of the spike known as HR1. By preventing HR1 from detaching from CH, the prefusion spike structure is stabilized without rigidification of the central helix or changes to its interaction with the receptor binding domain. This disulfide-stapled spike is more stable in the prefusion form, allowing for a stable vaccine without the need for the stabilizing mutations that are currently in use.
    Type: Application
    Filed: May 9, 2023
    Publication date: November 9, 2023
    Inventor: Carlos Simmerling
  • Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
    Publication number: 20230416343
    Abstract: The present disclosure provides fully human antibodies that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus with high affinity, or antigen-binding proteins derived from such antibodies, and uses thereof. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, that are coronavirus neutralizing antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein, including by intranasal delivery. Methods and compositions for treating or preventing coronavirus infection by administering a composition that includes a nucleic acid construct that encodes a neutralizing antibody are also provided.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 28, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Henry Hongjun Ji, Robert Allen, Heyue Zhou, Yanliang Zhang, Yanwen Fu, Wenzhong Guo, Hui Xie, Xia Cao, Lucy Lu, Donghui Li, Reyna Lim, Arthur Ledesma, Daniel Lee
  • Coronavirus Spike Glycoprotein With Improved Expression and Stability
    Publication number: 20230398204
    Abstract: The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an 51 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others.
    Type: Application
    Filed: October 21, 2020
    Publication date: December 14, 2023
    Inventors: Erica Ollman Saphire, Eduardo Olmedillas, Colin Mann
  • BINDING AGENTS FOR CORONAVIRUS S PROTEIN
    Publication number: 20230287088
    Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 14, 2023
    Inventors: Karsten Beckmann, Anna Carle, Sandra Prassl, Claudia Paulmann, Christiane Stadler, Georg Falck, Leyla Fischer, Alexander Muik, Ugur Sahin, Caroline Scharf
  • SARS-CoV-2 (COVID-19) spike-AXL binding assay
    Patent number: 11137395
    Abstract: The present disclosure an ELISA-based assay that uses a glycosylated s1F polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) spike protein, the N-terminal domain of which has affinity for the tyrosine-protein kinase receptor UFO (AXL). The S1F polypeptide can be generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed S1F polypeptide at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1F for AXL, provides a significant increase in the sensitivity of the assay compared to other known assays. Further the AXL polypeptide can be glycosylated, which further increases the affinity for S1F and AXL to each other.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: October 5, 2021
    Assignee: RayBiotech Life, Inc.
    Inventors: Ruo-Pan Huang, Tuhin Das, Hao Tang, Shuhong Luo, Jianmin Fang
  • S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USE
    Publication number: 20210403509
    Abstract: Described are S-layer fusion proteins comprising a self-assembling domain of a S-layer protein and a viral spike protein or a fragment thereof, a pharmaceutical composition (such as a vaccine) comprising the S-layer fusion protein, and method of immunizing a patient in need thereof comprising administering the vaccine.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 30, 2021
    Inventors: Uwe Sleytr, David Jin
  • CHIMERIC RSV AND CORONAVIRUS PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE
    Publication number: 20230248815
    Abstract: The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.
    Type: Application
    Filed: June 17, 2021
    Publication date: August 10, 2023
    Inventors: Martin Moore, Robert Jordan, Mariana Tioni
  • Stabilized Corona Virus Spike Protein Fusion Proteins
    Publication number: 20230302119
    Abstract: The present invention provides stabilized recombinant pre-fusion SARS CoV0-2 S proteins, nucleic acids molecules encoding the SARS CoV-2 S proteins and uses thereof.
    Type: Application
    Filed: July 5, 2021
    Publication date: September 28, 2023
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Jaroslaw JURASZEK
  • COVID-19 spike-ACE2 binding assay for drug and antibody screening
    Patent number: 11255855
    Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 22, 2022
    Assignee: RayBiotech Life, Inc.
    Inventors: Ruo-Pan Huang, Hao Tang, Shuhong Luo, Jianmin Fang
  • COVID-19 spike-ACE2 binding assay for drug and antibody screening
    Patent number: 11105804
    Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: August 31, 2021
    Assignee: RayBiotech Life, Inc.
    Inventors: Ruo-Pan Huang, Hao Tang, Shuhong Luo, Jianmin Fang
  • Covid-19 spike-ACE2 binding assay for drug and antibody screening
    Patent number: 11249083
    Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 15, 2022
    Assignee: RayBiotech Life, Inc.
    Inventors: Ruo-Pan Huang, Hao Tang, Shuhong Luo, Jianmin Fang
Narrow Results

Filter by US Classification